Clinical Trial Search

Primary: Morphine Equivalent Usage While in the Hospital — 29.59; 30.82; 10.54; 11.74 mg

Primary: Proportion of Female Respondents Having Their Preferences Based on Physician Gender for the OB/GYN Care — 667; 87; 261 Participants

Primary: Mean Doses Given — 93.9; 63.2; 58.63 Gy

Primary: Patient Reported Satisfaction — 54; 55 satisfaction score at baseline

Primary: PSQ-18 General Satisfaction — 4.0; 4.5 score on a scale

Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221

Primary: Acute Toxicity Rate — 6 percentage of participants

Primary: Percentage of Participants Who Underwent Gynecologic Surgery — 42; 32; 26 percentage of participants

Primary: Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC). — 15; 0 units on a scale — p=0.003

Primary: Procedure Completion — 7 participants

Primary: Urinary Tract Infections — 18; 10 participants

Primary: Hospital Stay — 3.0; 3.0 Days — p=0.36

Primary: Number of Participants Who Passed Bladder Trial — 25; 39 participants

Primary: Ovulation in Cycle 2 — 3; 2 Participants

Primary: Length of Hospitalization Post-operation — 8.92; 9.67 days — p=0.141

Primary: Number of Participants With Hospital Admission for Postoperative Pain Control — 23; 17; 10; 11 Participants

Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001

Primary: Number of Participants Confident in the Use of EHealth Format — 7 Participants

Primary: Relative Pain Scores, as Measured by the Pain Numeric Rating Scale (NRS) — 3.87; 4.95 score on a scale

Primary: Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit — 13 Participants

Primary: Serosal-anchor Measurement — 6.2 mm

Primary: Proportion of Patients Having Concurrent Apical Suspension Performed — 66 Participants

Primary: Percentage of Participants Retained in the Study — 78.6; 82.4 percentage of participants retained

Primary: Number of Oxycodone Tablets Used Day 1 — 1.0; 1.0 Oxycodone Tablets — p=.87

Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events

Primary: Length of Stay — 4.3; 3.3 days

Primary: Number of Patients With Venous Thromboembolism at Week 4 — 0 Participants

Primary: Feasibility - Enrollment — 32 Participants

Primary: Serum Concentrations of Estriol (E3) — 0; 0.91; 3.83; 1.58 pg/ml

Primary: Patients With Changes in Bone Marrow Assessed Through Images — 0; 4 Participants